SCHEMBL7247609

SCHEMBL7247609

COc1cc2c(cc1C=O)[C@](C)(C(F)(F)F)OC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.42
TACR1 P25103 3/20 0.42
CYP2D6 P10635 1/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KDM4E B2RXH2 2/20 0.41
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.36
MAPT P10636 2/20 0.36
POLA1 P09884 2/20 0.34
ESR1 P03372 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.33
RAB9A P51151 1/20 0.33
ERN1 O75460 3/20 0.33
PRKDC P78527 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6402101 1.00 ALDH1A1 (0.42) ALDH1A1TACR1CYP2D6GAASMN1; SMN2
SCHEMBL6400790 0.87 TACR1 (0.44) ALDH1A1TACR1CYP2D6GAASMN1; SMN2
SCHEMBL6406585 0.87 TACR1 (0.44) ALDH1A1TACR1CYP2D6GAASMN1; SMN2
SCHEMBL6400684 0.87 TACR1 (0.44) ALDH1A1TACR1CYP2D6GAASMN1; SMN2
SCHEMBL6401662 0.85 ALDH1A1 (0.43) ALDH1A1TACR1CYP2D6GAASMN1; SMN2
SCHEMBL6400844 0.78 ALDH1A1 (0.38) ALDH1A1TACR1CYP2D6GAASMN1; SMN2
SCHEMBL7530892 0.74 ALDH1A1 (0.41) ALDH1A1GAASMN1; SMN2KDM4ETSHR
SCHEMBL17591321 0.72 PDK2 (0.42) ALDH1A1TACR1CYP2D6MAPK1POLA1
SCHEMBL6401340 0.71 PDK2 (0.41) ALDH1A1TACR1CYP2D6ESR1
SCHEMBL6403380 0.71 PDK2 (0.41) ALDH1A1TACR1CYP2D6ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030208079-A1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists PFIZER INC. 2003-11-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030208079-A1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists TACR1, HRH2, GRPR ALDH1A1 308/4885TACR1 1/4885CYP2D6 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.